peptide

Overview

Peptides are short chains of amino acids linked by peptide bonds, typically consisting of 2–50 amino acids, that occupy a unique position in biomedical research and therapeutics. As molecular entities distinct from larger proteins yet capable of significant biological activity, peptides serve multiple roles in modern medicine, including as direct therapeutic agents, diagnostic tools, and scaffolds for drug delivery systems. In therapeutic applications, peptides function as targeted inhibitors of disease-associated proteins, immunomodulators, and components of engineered nanomaterials. Their programmable specificity, derived from precisely defined amino acid sequences and conformations such as beta sheet structures, makes them particularly attractive for precision medicine approaches targeting specific disease mechanisms with reduced off-target effects compared to small-molecule drugs.

Recent Publications Summary

Recent studies used peptide-based strategies to target protein-protein interactions and mutant or immune-related signaling nodes in cancer and inflammation. Structure-based design identified a highly potent peptide inhibitor of the microtubule-MAP7 interaction; peptide-3 bound microtubules with 0.12 μM affinity and suppressed colorectal cancer cell proliferation, migration, and invasion in HCT116 and SW480 cells, with in vivo antitumor activity and no obvious toxicity 42593932Aug. In parallel, virtual screening and experimental validation yielded a METTL3-targeting peptide, peptide-1, that bound METTL3 with Kd 0.76 ± 0.02 μM, reduced the METTL3-METTL14 NanoBRET signal, lowered cellular m6A and JUNB mRNA expression, and inhibited non-small cell lung cancer cell growth 42506933Jul. A separate structure-guided study identified an EGFR L858R-targeting peptide with strongest binding to the mutant receptor among screened candidates; peptide-1 reduced ovarian cancer cell viability, had weaker effects in nonmalignant cells, and its antiproliferative activity was attenuated by EGFR-targeting shRNA 42400372Jul.

Other publications focused on peptide ligands for immune and inflammatory signaling. A large virtual screening campaign discovered a STING-binding peptide, with peptide-1 showing the highest affinity (Kd 0.15 ± 0.01 μM), no apparent cytotoxicity up to 10 μM, and dose-dependent suppression of cGAMP-induced IFN-β and IL-6 expression, accompanied by reduced STING and IRF3 phosphorylation 42444292Jul. In cancer immunotherapy, dual-targeted S1R/PSMA peptide radioligands labeled with 161Tb showed stronger cytotoxicity and immunogenic cell death than 177Lu-labeled counterparts, induced more DNA double-strand breaks and reactive oxygen species, and produced complete regression in a murine prostate tumor model while sensitizing tumors to αPD1 blockade 42397707Jul. A RaPID-derived macrocyclic peptide inhibitor of ROR1/2 also showed potent single-digit nanomolar binding to ROR1 and strong growth inhibition across diffuse intrinsic pontine glioma cell lines by competing with the endogenous ligand Wnt5a 42260911Jun.

Beyond therapeutic targeting, peptides were also investigated as vaccine antigens, delivery cargos, and biomaterial components. A multi-peptide subunit vaccine for Mycobacterium avium subsp. paratuberculosis induced IFN-γ but lacked efficacy in a goat challenge trial 42501714Jul. In formulation research, spray freeze drying was explored to improve oral delivery of proteins and peptides through mucoadhesive microparticles, with excipient choice and drying conditions affecting particle properties and peptide-excipient interactions 41921708Apr. Another study used peptides derived from Tenebrio molitor larvae to produce nanoliposomes that encapsulated peptide fractions and improved liposome stability 42341964Jun. Peptide dendritic polymerization was further used to generate stable, tailorable nanoparticles that served as crosslinkers in multifunctional hydrogels, which showed antibacterial activity and enhanced infected wound healing efficacy 42012063Apr.

What Changes, What Holds

1. Peptide inhibitors are extending into highly specific intracellular oncogenic interfaces
REINFORCES Peptide-1 against microtubule-MAP7, METTL3, and mutant EGFR L858R strengthens the baseline claim that peptides can act as targeted inhibitors of disease-associated proteins with programmable specificity 42593932Aug42506933Jul42400372Jul. The new work does not replace the established therapeutic picture; it sharpens it by showing that structure-guided and virtual-screening approaches can yield peptides with measurable binding, selective antiproliferative activity, and in vivo antitumor effects across multiple cancer-relevant targets.

2. Peptides are also emerging as direct modulators of immune signaling and immunotherapy response
NEW DIRECTION STING-binding peptide-1 adds a role the Overview does not explicitly cover: peptide suppression of an inflammatory signaling node rather than merely inhibition of disease-associated proteins in general 42444292Jul. The radioligand and ROR1/2 studies still fit the baseline’s therapeutic scaffold, but they also extend peptides into immune activation, radiosensitization, and ligand competition in contexts where the key consequence is modulation of immunity or tumor–microenvironment interaction rather than classic target blockade 42397707Jul42260911Jun.

3. Peptide chemistry is broadening from therapeutics to formulation and biomaterials, with mixed translational payoff
REINFORCES Vaccine, spray-drying, nanoliposome, and hydrogel studies mainly confirm that peptides can function as delivery cargos and biomaterial components, consistent with the Overview’s framing 42501714Jul41921708Apr42341964Jun42012063Apr. At the same time, the goat challenge failure shows that immunogenicity alone does not establish efficacy for peptide vaccines, so the recent work sharpens rather than overturns the baseline by separating feasible platform use from proven clinical or veterinary benefit.

Overview update candidates: peptide inhibition of microtubule-MAP7, METTL3, and mutant EGFR; peptide modulation of STING and immune/radioimmunotherapy responses; peptide use in vaccine; oral-delivery; nanoliposome; and hydrogel biomaterial platforms.